H.C. Wainwright raised the firm’s price target on Akero Therapeutics to $43 from $40 and keeps a Buy rating on the shares post the Q4 report. The firm says a successful end-of-Phase 2 meeting with the FDA this month is the key inflection point for 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AKRO:
- Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Akero Therapeutics reports Q4 EPS (99c), consensus (86c)
- Madrigal opportunity in MASH remains after Boehringer data, says UBS
- Cantor biotech/biopharma analysts to hold analyst/industry conference call
- Biotech Alert: Searches spiking for these stocks today
